

Abstract of the Disclosure

The present invention relates to the discovery of antibodies able to modulate (prevent or favour) conversion of PrP^c to PrP^{Sc} and to their antigens. Depending on the nature of the antibodies (antagonistic or agonistic), their respective antigens are either conversion factors or
5 inhibitors of prion replication.